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Abstract
Background: Cruzain, the major cysteine protease of Trypanosoma cruzi, is an essential enzyme for the parasite life cycle
and has been validated as a viable target to treat Chagas’ disease. As a proof-of-concept, K11777, a potent inhibitor of
cruzain, was found to effectively eliminate T. cruzi infection and is currently a clinical candidate for treatment of Chagas’
disease.
Methodology/Principal Findings: WRR-483, an analog of K11777, was synthesized and evaluated as an inhibitor of cruzain
and against T. cruzi proliferation in cell culture. This compound demonstrates good potency against cruzain with sensitivity
to pH conditions and high efficacy in the cell culture assay. Furthermore, WRR-483 also eradicates parasite infection in a
mouse model of acute Chagas’ disease. To determine the atomic-level details of the inhibitor interacting with cruzain, a
1.5 A ˚ crystal structure of the protease in complex with WRR-483 was solved. The structure illustrates that WRR-483 binds
covalently to the active site cysteine of the protease in a similar manner as other vinyl sulfone-based inhibitors. Details of
the critical interactions within the specificity binding pocket are also reported.
Conclusions: We demonstrate that WRR-483 is an effective cysteine protease inhibitor with trypanocidal activity in cell
culture and animal model with comparable efficacy to K11777. Crystallographic evidence confirms that the mode of action
is by targeting the active site of cruzain. Taken together, these results suggest that WRR-483 has potential to be developed
as a treatment for Chagas’ disease.
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Introduction
American trypanosomiasis, or Chagas’ disease, is the third largest
parasitic disease burden in the world, and largest in the Western
hemisphere. [1] The disease is endemic in Central and South
America, and approximately 16 million people are currently afflicted.
Patients with Chagas’ disease develop flu-like symptoms during the
acute stage, followed by gastrointestinal lesions [2] and cardiopathy
[3] in the chronic stage. The etiological agent of Chagas’ disease is the
protozoan parasite, Trypanosoma cruzi, which is commonly transmitted
to the human host through the bite of the blood sucking triatomine
beetle, transfusion of infected blood, or mother-to-child transmission.
Nifurtimox and benznidazole, the two drugs used for treatment of
Chagas’ disease, have significant drawbacks, as they are at best
moderately effective in the chronic stages of the infection and cause
severe side effects. [4,5] Hence, the development of novel
therapeutics to effectively treat Chagas’ disease is essential.
The major cysteine protease of T. cruzi, cruzain, is an attractive
target for the development of trypanocidal agents. Cruzain is
expressed throughout the parasite life cycle and plays important
roles in the survival of the organism, including immunoevasion,
acquisition of nutrients, and parasite differentiation. [6] In
addition, the lack of redundancy of this enzyme makes the
parasites vulnerable to cruzain inhibition. In recent years, K11777
(1, Figure 1), a selective cruzain inhibitor, has been demonstrated
to eradicate T. cruzi infection in cell culture, mouse, and dog
models. [7,8,9] These studies prove that cysteine protease
inhibitors could serve as a viable agent for chemotherapeutic
intervention.
X-ray crystal structures of cruzain in complex with reversible
[10,11]and irreversible inhibitors [12,13,14,15,16,17] have been
reported, and the overall folding pattern and structure of the active
site is highly homologous to papain. Seven substrate binding sites,
four (S4,S 3,S 2, and S1) on the acyl side and three (S19,S 29, and
S39) on the amino side of the scissile bond, form a cleft between
two structural domains of the enzyme. The catalytic triad of
Cys25, His159, and Asn175, as well as the highly conserved
Trp177, is contained within this cleft. Like most other papain-like
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the complementary P2 residue is the key specificity determining
factor. Cruzain is able to accommodate phenylalanine or arginine
in the P2 position of the ligand due to the presence of Glu208
(cruzain numbering) found at the base of the S2 pocket, which can
form a salt bridge with the positively charged arginine side chain.
[13,18]
A varietyof cysteineprotease inhibitors have beenreported in the
literature. [19,20,21,22] In oneof ourgroup’sstrategiesindesigning
parasitic cysteine protease inhibitors, we have developed peptidyl
vinyl sulfones based on the pioneering work by Hanzlik [23]and
Palmer. [24]The vinyl sulfone warhead acts as a Michael acceptor
for the active site Cys25, while the sulfone unit and the peptide
framework provide several hydrogen bond acceptors that interact
favorably with complementary residues in the active site.[14] In our
earlier reports, we investigated the structure-activity relationship of
these inhibitors with variations on the vinyl sulfone substituent, the
P1 side chain, and the P3 group to generate a series of highly potent
cruzain inhibitors. [25] Further studies led to the identification of
compounds that effectively disrupted T. cruzi infection in cell culture
assays; [26]however, most of these compounds proved to be too
weak to be effective drugs in the in vivo mouse model. To date, all of
our compounds contain a hydrophobic group at the P2 site. Herein,
we report the synthesis of WRR-483 (2), the arginine variant of
K11777, its remarkable biological properties, and a crystalstructure
of WRR-483 bound to cruzain.
Methods
Chemistry: General methods
All reaction solvents were of reagent grade and used as received.
Tetrahydrofuran, dichloromethane, diethyl ether, and toluene
were purified by passing through a solvent column composed of
activated A-1 alumina. Unless indicated otherwise, all reactions
were conducted under an atmosphere of nitrogen using flame-
dried or oven-dried (170uC) glassware. Proton nuclear magnetic
resonance (
1H NMR) spectra and carbon-13 (
13C) NMR spectra
were recorded on commercially available NMR spectrometers at
400 MHz and 100 MHz, respectively. The proton signal for
residual, non-deuterated solvent (d 7.26 ppm for CHCl3, d
2.50 ppm for DMSO, and d 3.31 ppm for MeOD) was used as
an internal reference for
1H NMR spectra. For
13C NMR spectra,
chemical shifts are reported relative to the d 77.0 ppm resonance
of CDCl3, d 23.0 ppm for DMSO, or the d 49.0 ppm resonance of
MeOD. Coupling constants are reported in Hertz (Hz). Mass
spectra were recorded at the University of Michigan Mass
Spectrometry Laboratory.
Analytical thin layer chromatography (TLC) was performed on
Kieselgel 60 F254 glass plates pre-coated with a 0.25 mm thickness
of silica gel. The TLC plates were visualized with UV light and/or
by staining with either Hannesian solution (ceric sulfate and
ammonium molybdate in aqueous sulfuric acid) or permanganate
solution (potassium permanganate in aqueous sodium hydroxide).
Column chromatography was generally performed using Kieselgel
60 (230–400 mesh) silica gel, typically using a 50-100:1 weight
ratio of silica gel to crude product.
(S)-Benzyl 2-amino-5-(3-(2,2,4,6,7-pentamethyl-2,3-dihydro-
benzofuran-5-ylsulfonyl)guanidino)pentanoate (4). To a 0uC
solution of Na-(9-fluorenylmethoxycarbonyl)-Nv-(2,2,4,6,7-pentamet-
hyldihydrobezofuran-5-sulfonyl)-L-arginine (3, Fmoc-Arg(Pbf)-OH,
0.636 g, 0.980 mmol), benzyl alcohol (0.112 mL, 1.08 mmol), N-
methylmorpholine (0.120 mL, 1.09 mmol) and 4-dimethylamino-
pyridine (DMAP, 10 mg) in dichloromethane (CH2Cl2,1 0m L )w a s
added 1-ethyl-3-(39-dimethylaminopropyl)carbodiimide hydrochloride
(EDC, 0.223 g, 1.16 mmol). The resulting mixture was stirred for 1 h
at 0uC then 12 h at room temperature. The solvent was removed by
rotary evaporation, and the residue was treated with ethyl acetate
Figure 1. Structure of vinyl sulfone inhibitors, K11777 (1) and
WRR-483 (2). The P1 –P3 subsites of K11777 are labeled.
doi:10.1371/journal.pntd.0000825.g001
Author Summary
Current drugs for Chagas’ disease, caused by Trypanosoma
cruzi infection, are limited in efficacy and are severely toxic.
Hence the development of novel chemotherapeutic
agents targeting T. cruzi infections is an important
undertaking. In recent years, there has been considerable
interest in cruzain, the major protease in T. cruzi,a sa
target to treat Chagas’ disease. Herein, we present the
synthesis of WRR-483, a small molecule designed as an
irreversible cysteine protease inhibitor, and an assessment
of its biological activity against cruzain and T. cruzi
infection. This compound displays pH-dependent affinity
for cruzain and highly effective trypanocidal activity in
both cell cuture and a mouse model of acute Chagas’
disease. The crystal structure of WRR-483 bound to cruzain
elucidates the details of inhibitor binding to the enzyme.
Based on these results, this inhibitor is a promising
compound for the development of therapeutics for
Chagas’ disease.
Trypanocidal Properties of WRR-483 vs. T. cruzi
www.plosntds.org 2 September 2010 | Volume 4 | Issue 9 | e825(50 mL). The organic layer was washed with a saturated solution of
aqueous sodium bicarbonate (20 mL), brine (20 mL), dried over
Na2SO4, filtered, and concentrated to dryness to yield the crude benzyl
ester as a white foam. A solution of 20% piperidine in CH2Cl2
dichloromethane (4 mL) was added to the crude benzyl ester and the
mixture was stirred for 1 h at room temperature. The solvent was
removed by rotary evaporation and the residue was purified by flash
column chromatography (5–9% methanol in CH2Cl2)t og i v e
compound 4 (0.458 g, 0.886 mmol, 90% overall) as colorless foam:
1H NMR (400 MHz, CDCl3) d 7.34 (m, 5 H), 6.26 (br s, 1 H), 6.20 (s,
2 H), 5.12 (s, 2 H), 3.48 (m, 1 H), 3.14 (m, 2 H), 2.93 (s, 2 H), 2.56 (s, 3
H), 2.50 (s, 3 H),2.08 (s,3 H), 1.78 (m,1 H), 1.72 (s, 2 H),1.58 (m,3 H),
1.44 (s, 6H);
13C NMR (100 MHz, CDCl3) d 175.6, 158.9, 156.3,
138.5, 135.7, 133.2, 132.5, 128.9, 128.7, 128.6, 124.8, 117.7, 86.6,
67.1, 54.2, 43.4, 41.0, 28.8, 25.8, 19.5, 18.1, 12.7; HRMS (ES+) m/z
for C26H36N4NaO5S[ M +Na]
+ calcd 539.2304, found 539.2304.
(S)-Benzyl 2-(4-methylpiperazine-1-carboxamido)-5-(3-(2,2,4,
6,7-pentamethyl-2,3-dihydrobenzofuran-5-ylsulfonyl)guanidino)
pentanoate (5). As o l u t i o no fa m i n e4 (0.809 g, 1.57 mmol) in
CH2Cl2 (25 mL) was vigorously stirred for 30 min at 0uCw i t ha
saturated solution of aqueous sodium bicarbonate (25 mL). A solution of
triphosgene (0.155 g, 0.52 mmol) in CH2Cl2 (2 mL) was added and the
reaction mixture was stirred at 0uC for another 30 min. The layers were
separated and the aqueous layer was further extracted three times with
CH2Cl2 (10 mL). The combined organic layers were dried over
Na2SO4, filtered and cooled to 0uC. N-Methylpiperazine (0.156 g,
1.56 mmol) was added to the solution. This mixture was stirred
overnight and then concentrated to dryness. Purification of the residue
by flash column chromatography (7–12.5% methanol in CH2Cl2)g a v e
0.939 g (93% overall) of urea 5 as colorless foam:
1H NMR (400 MHz,
CDCl3) d 7.33 (m, 5 H), 6.32 (br s, 1 H), 6.23 (br s, 2 H), 5.37 (d,
J=7.2 Hz, 2 H), 5.20 (d, J=12.3 Hz, 1 H), 5.15 (d, J=12Hz,1H),
4 . 5 0( m ,1H ) ,3 . 3 8( a p pt ,J=4 . 8H z ,4H ) ,3 . 2 9( b rs ,1H ) ,3 . 1 4( b rs ,1
H ) ,2 . 9 3( s ,2H ) ,2 . 5 5( s ,3H ) ,2 . 4 9( s ,3H ) ,2 . 3 3( a p pt ,J=4.8 Hz, 4 H),
2 . 2 7( s ,3H ) ,2 . 0 7( s ,3H ) ,1 . 8 0 – 1 . 9 1( m ,1H ) ,1 . 5 7 – 1 . 6 9( m ,3H ) ,1 . 4 4
(s, 6H);
13C NMR (100 MHz, CDCl3) d 173.5, 159.0, 157.7, 156.5,
138.7, 135.5, 133.5, 132.6, 129.0 (two peaks), 128.7, 124.9, 117.8, 86.7,
67.8, 54.9, 46.4, 44.1, 43.6, 41.1, 31.6, 29.0, 25.3, 19.6, 18.2, 12.8;
HRMS (ES+) m/z for C32H46N6NaO6S[ M +Na]
+ calcd 665.3097,
found 665.3099.
(S)-2-(4-Methylpiperazine-1-carboxamido)-5-(3-(2,2,4,6,7-
pentamethyl-2,3-dihydrobenzofuran-5-ylsulfonyl)guanidino)
pentanoic acid (6). Urea 5 (1.65 g, 2.57 mmol) was dissolved in
a mixture of ethyl acetate (4 mL) and methanol (16 mL). To this
solution was added 10% palladium on carbon (0.25 g) and the
reaction was stirred under a hydrogen atmosphere using a balloon
filled with hydrogen gas for 20 h at room temperature. After
removal of the catalyst by filtration through a pad of CELITE
TM,
the filtrate was concentrated in vacuo to afford 1.31 g (92%) of acid 6
as a colorless solid:
1H NMR (400 MHz, MeOD-d4) d 4.17 (dd,
J=8.0, 4.8 Hz, 1 H), 3.62 (m, 4 H), 3.17 (m, 2 H), 2.99 (m, 6 H),
2.70(s,3H),2.57 (s,3 H),2.51(s,3 H),2.08 (s,3 H),1.81–1.88(m,1
H), 1.65–1.70 (m, 1 H), 1.57–1.63 (m, 2 H), 1.45 (s, 6 H);
13C NMR
(100 MHz, MeOD-d4) d 178.6, 159.9, 159.1, 158.2, 139.4, 133.5,
118.5, 87.7, 56.3, 54.7, 44.5, 44.0, 41.7, 30.8, 28.7, 27.1, 19.6, 18.4,
12.5; HRMS (ES+) m/z for C25H40N6NaO6S[ M +Na]
+ calcd
575.2628, found 575.2615.
4-Methyl-N-((S)-1-oxo-5-(3-(2,2,4,6,7-pentamethyl-2,3-di-
hydrobenzofuran-5-ylsulfonyl)guanidino)-1-((S,E)-5-phenyl-
1-(phenylsulfonyl)pent-1-en-3-ylamino)pentan-2-yl)pipera-
zine-1-carboxamide (8). Vinyl sulfone 7 (0.864 g, 2.15 mmol)
was dissolved in a solution of 33% trifluoroacetic acid in CH2Cl2
(7.5 mL) and the mixture was stirred in an ice bath for 2 h. The
solvent was removed, and the excess trifluoroacetic acid was
removed by repeated evaporation with toluene in vacuo. The crude
amine (as the TFA salt) was treated with CH2Cl2 (10 mL) and
enough dimethylformamide (DMF, ca. 2 mL) to give a clear
solution. To this solution were added acid 6 (1.19 g, 2.16 mmol),
N-hydroxybenzotriazole (HOBT, 0.363 g, 2.37 mmol), N-methy-
lmorpholine (0.474 mL, 4.32 mmol), and 1-ethyl-3-(39-dimethy-
laminopropyl)carbodiimide hydrochloride (EDC, 0.454 g, 2.37
mmol). The resulting mixture was stirred at 0uC then warmed to
room temperature over 11 h. After removal of solvent by rotary
evaporation, the residue was dissolved in ethyl acetate (80 mL) and
extracted with saturated aqueous solution of sodium bicarbonate
(20 mL). The layers were separated and the organic layer was
washed with brine (20 mL), dried over sodium sulfate, filtered, and
the solvent was removed in vacuo. Purification of the crude product
by flash column chromatography (11–14% methanol in CH2Cl2)
provided 1.56 g (84%) of vinyl sulfone 8 as a colorless solid:
1H
NMR (400 MHz, DMSO-d6) d 7.99 (d, J=8.4 Hz, 1H), 7.82 (d,
J=7.2 Hz, 2H), 7.70 (t, J=7.4 Hz, 1H), 7.62 (t, J=7.4 Hz, 2H),
7.25 (t, J=7.6 Hz, 2H), 7.16 (t, J=7.0 Hz, 3H) 6.87 (dd, J=15.2,
4.8 Hz, 1H), 6.70 (dd, J=15.2, 1.6 Hz, 1 H), 6.60–6.90 (br s, 1 H),
6.46 (d, J=7.6 Hz, 1 H), 6.38 (br s, 1 H), 4.45 (m, 1 H), 3.99 (m, 1
H), 3.29 (m, 4 H), 3.02 (m, 2 H), 2.95 (s, 2 H), 2.54–2.61 (m, 1 H),
2.48 (s, 3 H), 2.43 (s, 3 H), 2.40–2.51 (m, 1 H), 2.21 (m, 4 H), 2.14 (s,
3 H), 2.00 (s, 3 H), 1.89–1.96 (m, 1 H), 1.72–1.81 (m, 1 H), 1.54–
1.64 (m, 2 H), 1.40 (s, 6H), 1.31–1.48 (m, 2 H);
13CN M R
(100 MHz, DMSO-d6) d 172.8, 157.4, 157.3, 156.0, 147.1, 141.1,
137.3, 133.6, 131.4, 12.8, 129.6, 128.3, 127.0, 125.8, 124.3, 116.2,
86.3, 54.5, 54.4, 48.5, 45.7, 43.4, 42.4, 40.1, 39.9, 39.7, 39.5, 39.3,
39.1, 38.9, 34.5, 31.3, 28.8, 28.3, 18.9, 18.5, 17.6, 12.3; HRMS
(ES+) m/z for C42H58N7O7S[ M +H]
+ calcd 836.3834, found
836.3869.
WRR-483 (2). Trifluoroacetic acid (3 mL) was added to a
solution of the protected vinyl sulfone 8 (0.4056 g, 0.485 mmol) in
CH2Cl2 (1 mL) at 0uC and the reaction mixture was stirred for
4.5 h. The solvent was removed under reduced pressure and
excess trifluoroacetic acid was removed by repeated evaporation
with toluene in vacuo. The crude product was triturated in Et2O
and the solvent was decanted. The solid residue was dissolved in
0.2 N HCl (15 mL) and washed four times with ethyl acetate
(10 mL). Water was removed in vacuo and the resulting oil was
triturated with acetonitrile to give 0.273 g (86%) of WRR-483 (2)
as a colorless solid (HCl salt):
1H NMR (400 MHz, MeOD-d4) d
7.88 (d, J=7.2 Hz, 2 H), 7.70 (t, J=7.6 Hz, 1 H); 7.61 (t,
J=7.6 Hz, 2 H), 7.24 (t, J=7.6 Hz, 2 H), 7.16 (m, 3 H), 6.89 (dd,
J=15.0, 5.0 Hz, 1 H), 6.66 (dd, J=14.8, 1.6 Hz, 1 H), 4.55 (m, 1
H), 4.31 (br s, 2 H), 4.14 (dd, J=8.0, 6.4 Hz, 1 H), 3.50 (br s, 2 H),
3.22 (t, J=6.4 Hz, 4 H), 3.10 (br s, 2 H), 2.93 (s, 3 H), 2.71 (ddd,
J=13.6, 8.8, 5.6 Hz, 1 H), 2.61 (m, 1 H), 1.96 (m, 2 H), 1.83 (m, 2
H), 1.75 (m, 1 H), 1.66 (m, 1 H);
13C NMR (100 MHz, MeOD-d4)
d 175.3, 158.8, 158.6, 147.6, 142.2, 141.8, 134.9, 132.2, 130.6,
129.6, 129.5, 128.7, 127.2, 56.9, 4.4, 50.7, 43.7, 42.5, 42.1, 36.1,
33.2, 30.1, 26.7; HRMS (ES+) m/z for C29H42N7O4S[ M +H]
+
calcd 584.3019, found 584.3026.
Enzyme assays
Cruzain[27,28], rhodesain [29], and tbcatB [30] were recom-
binantly expressed as described previously. TbcatB assays were
performed as described previously.[31] Cruzain (2 nM) or
rhodesain (3 nM) was incubated with 0.5 to 10 mM inhibitor
concentration in 100 mM sodium acetate at pH 5.5, containing
5 mM DTT (buffer A) for 5 min at room temperature. Then
buffer A containing Z-Phe-Arg-AMC (Bachem, KM=1mM) was
added to enzyme inhibitor to give 20 mM substrate concentration
in 200 mL, and the increase in fluorescence (excitation at 355 nm
Trypanocidal Properties of WRR-483 vs. T. cruzi
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microtiter plate spectrofluorometer (Molecular Devices, Flex
station). Inhibitor stock solutions were prepared at 20 mM in
DMSO, and serial dilutions were made in DMSO (0.7% DMSO
in assay). Controls were performed using enzyme alone and
enzyme with DMSO. IC50 values were determined graphically
using inhibitor concentrations in the linear portion of a plot of
inhibition versus log[I] (seven concentrations tested with at least
two in the linear range).
For pH dependence studies, cruzain was tested at 4 nM in
5 mM Z-Phe-Arg-AMC in 0.15 M citrate phosphate buffer at
pH 5.5 and pH 8.0 with 5 mM DTT, and 0.01% Triton-X 100.
Enzyme was added to wells of a 96-well microtiter plate containing
substrate and inhibitor diluted in DMSO (0.5% final concentra-
tion), or DMSO control. Final inhibitor concentration ranged
from 0.01 mMt o1 0mM. Experiments were done in triplicate.
Assays were run at 25uC in an automated microtiter plate
spectrofluorometer, with robotic delivery of enzyme and readings
every 1.52 seconds throughout the assay, before and after enzyme
addition.
Inhibitor dilutions which produce simple exponential progress
curves over a wide range of kobs, were used to determine kinetic
parameters. The value of kobs, the rate constant for loss of enzyme
activity, was determined from an equation for pseudo first order
dynamics using Prism 4.0 (GraphPad). When kobs varied linearly
with inhibitor concentration, kass was determined by linear
regression analysis. If the variation was hyperbolic, indicating
saturation inhibition kinetics, kinact and Ki were determined from
an equation describing a two-step irreversible inhibitor mechanism
[kobs=kinact [I]o/([I]o+Ki* (1+[S]o/KM))] and non-linear regression
analysis Prism 4.0.[32] All values were corrected for substrate
concentration.
T. cruzi cell culture assay
CA-I/72 T. cruzi parasites were isolated from a chronic
Chagasic patient, cloned, and maintained as previously de-
scribed.[33]
For growth inhibition studies, J774 macrophages cultured in
RPMI-1640 medium with 5% heat inactivated fetal calf serum
(FCS) were irradiated (9000 rad) to arrest the cell cycle and plated
onto 12-well tissue culture plates for 24 h at 37uC. After infection
with 10
5 T. cruzi trypomastigotes per well for 2 hours, monolayers
were washed with RPMI medium and treated with the inhibitors
at 10 mM in RPMI medium (triplicate wells per inhibitor).
Inhibitor stocks were made to 10 mM in DMSO and diluted
prior to use. All assays include untreated, K11777-treated, and
uninfected macrophage controls. Fresh medium with or without
inhibitor was replaced every 48 h and inhibitor efficacy was
monitored daily. Survival time was defined as the time before the
cell monolayer was destroyed by the infection. Under these culture
conditions, T. cruzi completed the intracellular cycle in 6 days in
untreated controls. Treatment duration was up to 27 days as such
regime results in cure of macrophages treated with 10 mM K11777
(positive control). Macrophages were subsequently cultured in
normal medium for up to 40 days to elucidate if the effective
inhibitors were trypanocidal (cure host macrophages) or trypano-
static (delay intracellular cycle of the parasite).
For dose-response studies, bovine embryo skeletal muscle
(BESM) cells were infected with T. cruzi as previously described
with minor modifications.[34] Briefly, 150 mL of RPMI medium
containing 1000 BESM cells were seeded per well in a 96-well
plate and incubated for 4 h at 37uC to allow cell attachment.
Monolayers were then infected with 1000 trypomastigotes/well of
CA-I/72 T. cruzi for 2 h at 37uC. Cells were washed once with
200 mL of sterile PBS and medium was replaced with WRR-483 at
the following concentrations: 20, 10, 7.5, 5, 2.5, 1.25, 0.6 and
0.3 mM. Cultures were then incubated for 72 h at 37uCi na
humidified atmosphere with 5% CO2. Cultures were next fixed in
4% fresh paraformaldehyde in PBS, stained with DAPI, and
counted under a fluorescence microscope (4006). Mean numbers
of parasites per cell (6SE) were calculated as previously reported
(n=3–4 per concentration). Controls consisted of untreated wells
and cultures similarly treated with 10 mM K777 and 0.1 mM
posaconazole.
In vivo studies
Ethics statement. These studies were performed in strict
accordance with the recommendations in the Guide for the
University of California San Francisco Institutional Animal Care
and Use Committee. The protocol was approved by the
Committee on the Ethics of Animal Experiments of the
University of California San Francisco (Permit Number:
AN080380-02). All surgery was performed under sodium
pentobarbital anesthesia, and all efforts were made to minimize
suffering.
Three to four week old female C3H mice weighing ca. 20 g were
used. The animals were separated into five lots of 5 mice per cage
and infected with 10
6 tissue-culture derived trypomastigotes of the
myotropic T. cruzi CA-I/72 cloned stock. The mice were treated
with 100 mg compound/kg of body weight in 100 mL of solution
(30–40% DMSO: 60–70% sterile distilled water) intraperitoneally
twice a day. Treatment was initiated 12 h post infection and
continued until cure, death of the animals, or for a total of 20 days.
Controls included one lot of infected, untreated animals and
another lot of infected animals treated daily with 100 mg
K11777/kg weight in two daily doses. Parasitemias was deter-
mined at the end of the experiment when animals were
euthanized. Tissues processed for histopathology include skeletal
muscle, heart, liver, spleen, and colon. Blood (5–50 mL) was used
for hemocultures. Hemocultures were considered negative if no
parasites were observed for 60 days. Treatment was considered
effective if life expectancy is increased in treated animals compared
to untreated controls, symptoms of acute Chagasic infection were
absent, and histopathological observation showed normal tissues
and no parasites. Compounds were considered toxic if life
expectancy is lower than untreated controls (negative values). If
necessary, PCR of blood and tissues was performed to confirm
effectiveness of treatment and/or cure of treated animals. Results
were expressed as survival (days) of treated animals.
Preparation, purification and crystallization of cruzain
bound to WRR-483
Cruzain was expressed and purified as described previously.[27]
Activated cruzain was incubated overnight with molar excess
amounts of inhibitor dissolved in DMSO. This prevented further
proteolytic activity and lack of activity was confirmed via
fluorometric assay against the substrate Z-Phe-Arg-AMC (Ba-
chem, KM=1mM). After passage over a MonoQ column, fractions
containing pure inhibited cruzain were concentrated, to a final
concentration of 10 mg/mL, with a Viva-Spin (Viva Science)
column (MWCO 15 kDa). Simultaneous with concentration,
buffer exchange to 2 mM bis-tris at pH 5.8 was performed.
Crystals of maximum size were obtained after approximately 1
week via the hanging drop method, from a precipitating agent of
1.26 M (NH4)2SO4, 0.2 M LiSO4, at pH 6.0. Crystals were flash-
cooled in liquid nitrogen after a 5 second soak in 20% ethylene
glycol and loaded into a SAM (Stanford Auto Mounter) cassette
for crystal screening.[35]
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refinement
All diffraction data were collected at the Stanford Synchrotron
Radiation Laboratory (SSRL), beamline 9-1, using monochro-
matic radiation of 0.98 A ˚, after selecting an optimal crystal from
screening performed with the robotic SAM system. An ADSC
Quantum 315 3x3 CCD array detector was used with low
temperature conditions of 103 K at the crystal position. Data
processing was completed with MOSFLM [36] and SCALA. The
structure was solved via molecular replacement using the
MOLREP program of the CCP4 suite [37] with a model derived
from cruzain bound to a different vinyl-sulfone containing
inhibitor (PDB ID 1F2A), with inhibitor and water molecules
removed from the search model. The topmost solution contained
two unique monomers related by an NCS two-fold axis of
symmetry. The solution was 82.2 s above noise level, with an
Rfactor of 0.493. Iterative rounds of manual model building and
refinement were completed with COOT and Refmac5 with
isotropic temperature factors. The inhibitor molecule was
manually placed and fit to electron density using COOT. Clear
and representative density for the entirety of both inhibitor
molecules in the asymmetric unit was observed at better than 1.5 s
above the noise level. Water molecules were placed with COOT
and manually assessed. Molecules of the cryoprotectant ethylene
glycol and the crystallization precipitant ammonium sulfate were
also discernable in final electron density maps of this structure and
were placed using COOT and refined with Refmac5. All statistics
for data collection, structure solution and refinement are given in
Table 1. The coordinates and observed structure factor amplitudes
for the refined structure have been deposited in the Protein Data
Bank under accession code 3LXS.
Results
Synthesis of WRR-483 (2)
The synthesis of WRR-483 is summarized in Figure 2.
Esterification of commercially available Na-Fmoc-Nv-(2,2,4,6,7-
pentamethyldihydrobenzofuran-5-sulfonyl)-L-arginine (3) with
benzyl alcohol, followed by Fmoc removal gave amine 4. Amine
4 was converted to an isocyanate by treatment with triphos-
gene;[38] subsequent addition of N-methylpiperazine afforded
urea 5. Deprotection of the carboxylic acid by hydrogenolysis gave
the carboxylic acid 6. The tert-butyl carbonate blocking group of
vinyl sulfone 7[24] was removed and the resulting amine was
coupled with acid 6 to give vinyl sulfone 8 in 84% overall yield.
Finally, the 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl
(Pbf) group was removed by treatment of 8 with trifluoroacetic
acid in dichloromethane to provide WRR-483 (2).
Biological effects of WRR-483
WRR-483, a K11777 analog, which replaces phenylalanine
with arginine at the P2 position, was previously reported as an
effective inhibitor of the Entamoeba histolytica cysteine protease 1
(EhCP1). [39] EhCP1 displays a high preference for arginine at P2
that is unusual among the papain-like protease family. In addition,
this inhibitor was also demonstrated to successfully reduce amebic
invasion in the human colonic xenograft model by 95%.[39]
Cruzain is a dual-specific protease that binds to substrates
containing phenylalanine or arginine in the P2 site, with a
preference for phenylalanine over arginine.[13,18] Hence, we
anticipated that WRR-483 would inhibit cruzain, but with lesser
efficacy compared to K11777. The inhibitors were also assayed
against rhodesain, a closely related enzyme in the protozoan
parasite, T. brucei. Rhodesain lacks the critical glutamate residue at
the S2 site for arginine binding, and was reported to be inactive
against substrates with arginine at P2.[29] Therefore, selectivity for
cruzain over rhodesain was anticipated. In the study of irreversible
inhibitors, IC50 values are highly dependent on assay methods and
enzyme concentration, hence the second-order rates of inhibition
were determined. As summarized in Table 2, WRR-483 was a
modest inhibitor of cruzain, with a kobs/[I] value of 4,800 s
21M
21
In comparison, K11777 was more effective than WRR-483 by
over 20-fold. As expected, WRR-483 showed no inhibition of
rhodesain, even at 10 mM concentration. K11777 and WRR-483
were also assayed against tbcatB, the putative essential protease of
T. brucei,[30] but both compounds were weak inhibitors.
Table 1. Crystallographic parameters: data collection and
refinement statistics (for high resolution bin, statistics are
given in parentheses).
Data Collection
Resolution (A ˚) 1.50
Space group C2
Unit cell parameters
a( A ˚) 134.35
b( A ˚) 38.14
c( A ˚) 95.16
b (u) 114.36
Wavelength (A ˚) 0.98
Temperature (K) 103
Total number reflections 374500
Total unique reflections 70666
Completeness 99.2 (99.7)
Redundancy 5.3 (5.4)
Rsym 0.057 (0.182)
I/sI 19.3 (8.9)
Refinement
Resolution range (A ˚) 45.31 – 1.50 (1.54 -1.50)
Rfactor 0.122 (0.121)
Rfree 0.158 (0.181)
Average B factor (A ˚2)
ethylene glycol 26.50
inhibitor 13.08
protein 10.01
sulfate 32.60
water 24.00
R.m.s deviation from ideal
Bond lengths (A ˚) 0.017
Bond angles (u) 1.76
Ramachandran analysis (MolProbity)
Residues in favored regions (%) 97.9
Residues in allowed regions (%) 100
Residues in disallowed regions (%) 0
Molprobity
Score 2.48
Percentile 99%
PDB ID 3LXS
doi:10.1371/journal.pntd.0000825.t001
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because cruzain has ca. 35% of its maximal activity for arginine
containing ligands at pH 5.5.[13,18] Thus, WRR-483 was re-
evaluated in a different buffer condition at a range of pH values. By
switching from acetate to a citrate-phosphate buffer, a slight
improvement in enzyme activity and inhibitor potency was observed
at pH 8.0. The IC50 value of WRR-483 showed an almost 10-fold
improvement at pH 8.0 than at pH 5.5; however, there was only a 4-
fold increase in the second-order rate of inactivation. On the other
hand, K11777 showed a consistent IC50 value at pH 5.5 and 8.0,
while kinact/[Ki] decreased from 1,030,000 to 234,000 (Table 3).
WRR-483 was then tested for its potency on arresting the
intracellular growth of T. cruzi infection in J774 macrophages. The
effectiveness of the inhibitor was determined by the number of days
the lifetime of the treated infected cells were prolonged compared to
the control (Table4). In the absence of the inhibitor,parasite-infected
macrophage controls lysed in six days, due to the completion of the
parasite intracellular replication cycle. Surprisingly, at 10 mM,WRR-
483 was as effective as K11777 in eliminating the parasite from the
host cells, as the cultures with the vinyl sulfones stayed intact until the
experiment was terminated. Even after inhibitor treatment was
ceased on the 27
th day, no re-emergence of parasite infection was
Figure 2. Synthesis of WRR-483 (2): (a) (i) benzyl alcohol (BnOH), 4-dimethylaminopyridine, 1-ethyl-3-(39-dimethylaminopropyl)carbodiimide
hydrochloride (EDC), N-methylmorpholine, CH2Cl2; (ii) piperidine, CH2Cl2, 90% (two steps); (b) (i) triphosgene, sodium bicarbonate (NaHCO3), CH2Cl2;
(ii) N-methylpiperazine, CH2Cl2, 93% (two steps); (c) H2, 5% palladium on carbon (Pd/C), MeOH, 92% (d) (i) trifluoroacetic acid (TFA), CH2Cl2; (ii) 6,N -
hydroxybenzotriazole (HOBT), 1-ethyl-3-(39-dimethylaminopropyl)carbodiimide hydrochloride (EDC), N-methylmorpholine, dimethyl formamide
(DMF), CH2Cl2, 84%; (g) 3:1 TFA:CH2Cl2, 86%.
doi:10.1371/journal.pntd.0000825.g002
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ended. Determination of dose response of the activity of WRR-483
against T. cruzi infection in BESM cells demonstrated that WRR-483
had an EC50 of 0.2 mM, which was more effective than K11777 and
comparable to posaconazole (EC50=4.2 and 0.2 mM for K11777
and posaconazole, respectively).[34]
Murine model studies
Encouraged by the anti-parasitic activity in the macrophage
assay, WRR-483 was further evaluated in vivo. In a murine model of
acute Chagas’ disease, mice were exposed to 10
6 trypomastigotes of
the virulent CA-I/72 clone (Table 5). All untreated control mice
infected with T. cruzi died within 21–60 days while all mice treated
with WRR-438 or K11777 survived the acute infection and
appeared healthy and normal. Tissues inspected histologically
including heart and skeletal muscle were normal and free of
parasites in 3/5 mice treated with WRR-483 and 3/5 mice treated
with K11777; 2/5 mice in each group had 1–3 nests of amastigotes
visible in skeletal muscle while heart tissue was normal or presented
mild inflammatoryinfiltrate.Incontrast,5/5 untreatedcontrolshad
T. cruzi amastigotes and intense or moderate inflammation in heart
and/orskeletalmuscle.Hemocultureswerenegative forallinhibitor
treated mice and positive for untreated controls.
Protease inhibition profiling
To identify any possible off-target activity, and to assess
selectivity, WRR-483 and K11777 were screened against a panel
of 70 proteases (Reaction Biology Corp). The proteases that
WRR-483 and K11777 inhibited with IC50 values less than
10 mM are shown in Table 6. The inhibitors were active against
only papain and a few of the papain-like members of the cathepsin
family, particularly cathepsins B, C, and S. However, potency of
WRR-483 against papain, cathepsins L and V were moderate, and
no inhibition of other cysteine proteases, including calpain-1,
cathepsins H and K, was observed. Overall, the selectivity profile
of WRR-483 was comparable to K11777, but WRR-483 had a
lower affinity for all proteases except for cathepsin B.
Structure determination
A 1.5 A ˚ crystallographic structure of cruzain with WRR-483
was determined. Two unique complexes (A and C) of cruzain
covalently bound to the inhibitor WRR-483 comprise the
crystallographic unit (Figure 3). The two cruzain molecules are
nearly identical in structure, with a RMS distance of 0.17 A ˚ when
superimposed upon one another. The two inhibitor molecules are
also nearly identical in conformation and placement within the
active site of cruzain, with the exception of the conformation of the
N-methyl-piperazine group at the P3 position. The packing of the
asymmetric unit reveals that the opening of the active site cleft of
each cruzain molecule points toward the other, such that the two
WRR-483 molecules within the asymmetric unit are directly
adjacent to one another. The homophenylalanine moiety of the
inhibitor molecules come within a 3.6 A ˚ distance of one another at
the point of closest proximity. This packing appears to be an
artifact of crystal packing in this space group, with these
crystallization conditions.
The WRR-483 inhibitor molecule is covalently bound to the
active site cysteine via Michael addition, at a distance of 1.84 A ˚ in
complex A and 1.83 in complex C (Figure 3b). Other points of
contact between cruzain and the inhibitor are fairly consistent
between complex A and C. The vinyl sulfone moiety makes several
constructive interactions to the protein. One of the vinyl sulfone
oxygens forms hydrogen bonds with His162 Nd1 (3.39 A ˚ in
complex A, 3.43 A ˚ in complex C), Gln19 Ne2 (3.09, 2.90 A ˚) and
with Gln 19 Oe1 (2.94 A ˚, complex A) while the other oxygen
makes a 2.98 A ˚ hydrogen bond to an ethylene glycol molecule in
complex A. This nexus of interactions is consistent with what was
observed in several other X-ray crystal structures of cruzain with
bound vinyl sulfone inhibitors.[14,16] When the cruzain-WRR-
483 structure is superimposed on several other structures of
cruzain bound to vinyl-sulfonyl containing inhibitors (PDB 1F2A,
1F2B, 1F2C, 2OZ2), the positioning and orientation of the vinyl
sulfone moieties are nearly perfectly aligned (data not shown).
Hydrogen bonding interactions between cruzain and the
peptide backbone of WRR-483 are consistent with the previously
reported complexes. These include hydrogen bonding between the
Table 2. Kinetic data for vinyl sulfone inhibitors against cruzain, rhodesain, and tbcatB.
kobs/[I] at 1 mM( s
-1 M
-1) tbcatB % inhibition at 1 mM tbcatB kass (s-1 M-1)
Cmpd Cruzain Rhodesain
K11777 108,00064,200 48,000610,200 48 5006100
WRR-483 4,8006480 No inhibition 26 Not determined
doi:10.1371/journal.pntd.0000825.t002
Table 3. pH dependence of cruzain inhibition.
IC50 (nM) kinact/Ki (s
-1 M
-1)
Cmpd pH 5.5 pH 8.0 pH 5.5 pH 8.0
K11777 1.560.8 260.3 1,030,000640,000 234,000612,000
WRR-483 70630 8621 4 , 0 0 0 6240 62,0006350
doi:10.1371/journal.pntd.0000825.t003
Table 4. Results of inhibitors on survival of J774 cells and
mice infected by T. cruzi.
Compound
T. cruzi infected cell
survival (days)
a
T. cruzi infected mouse
survival (days)
b
Control 6 21
K11777 47 110
WRR-483 47 110
aJ774 macrophages infected with T. cruzi were treated every 48 h until Day 27
with a solution of inhibitor (10 mM). Survival time is defined as the number of
days before the cell monolayer is destroyed by the infection. Experiment was
terminated on Day 47.
bInfected mice were treated with 100 mg inhibitor/kg body weight in two daily
doses.
doi:10.1371/journal.pntd.0000825.t004
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(2.89, 2.86 A ˚), the peptidyl nitrogen of Gly66 with the amide
oxygen of WRR-483 (3.00, 3.02 A ˚), and the peptidyl oxygen of
Gly66 with the urea nitrogen of WRR-483 (2.85, 2.91 A ˚).
Hydrogen bonding interactions are also formed between the urea
carbonyl oxygen of the inhibitor and two water molecules in
complex A at distances of 2.83 A ˚ and 3.36 A ˚. In complex C, there
is one such interaction at this point, at a distance of 2.83 A ˚. Like
the other vinyl sulfone inhibitors, the homophenylalanine side-
chain extends into the solvent without making any favorable
contacts with the enzyme.
The most interesting of interactions, because they are located
within the bottom of the S2 pocket, the site known to impact
substrate preference profiles for papain-family cysteine proteases,
are with the Arg moiety of WRR-483. The Ne of the Arg moiety
of WRR-483 makes contacts with the Oe2 of Glu208 at distances
of 2.84 A ˚ and 2.81 A ˚ in the two complexes. The Ng of the
inhibitor arginine moiety binds to the Oe1 of Glu208, at distances
of 2.89 and 2.89 A ˚. The remaining hydrogen bond contacts with
the arginine group of the inhibitor are to the amide nitrogen. In
complex A, there is a hydrogen bond formed to a water molecule
at a distance of 2.99 A ˚.
Discussion
Kinetic studies indicate that WRR-483 is a modest inhibitor of
cruzain. This compound is more potent at higher pH levels, but it
still relatively weak when compared to K11777. Yet, in the in vitro
cell assay, this compound demonstrates trypanocidal activity
comparable to the lead compound, K11777, and is unexpectedly
effective in curing acute T. cruzi infection in mice. Crystallographic
evidence indicates that WRR-483 indeed binds to cruzain in a
similar fashion compared to other vinyl sulfone analogs, with the
addition of hydrogen bonding interactions between Glu208 in the
S2 pocket and the arginine side chain of the inhibitor. The
structure of cruzain bound to another irreversible inhibitor
containing an arginine in the P2 position has been solved
previously.[13] In this structure, two conformations of the arginine
side chain of Z-Arg-Ala-FMK have been modeled at partial
occupancies, with the one identified as more physiologically
relevant at ca. 70% occupancy (PDB ID 2AIM). In the major
conformation, the NH1 and NH2 of the arginine moiety form a
substrate-directed salt bridge to the glutamate in the base of the S2
pocket. The glutamate (Glu 205) side chain is oriented such that it
points into the S2 pocket, towards the guanidine group. This is in
Table 5. Histopathology of mice infected by T. cruzi.
Treatment Animal ID# Heart Sk. muscle Liver Spleen Colon
Untreated controls 307-1-1 +A i/i +10A Intense i/i Necrosis N N N
307-1-2 i/i +A i/i N N N
307-1-3 i/i +A i/i N N N
307-1-4 i/i +A i/i N N N
307-1-5 i/i +A
Intense i/i
NN N
WRR-483 307-2-1 Mild i/i +A
Intense i/i
NN N
307-2-2 N +A
Intense i/i
NN N
307-3-3 N Moderate i/i N N N
307-3-4 N Moderate i/i N N N
307-3-5 N Moderate i/i N N N
K11777 307-5-1 Mild i/i +A
Intense i/i
NN N
307-5-2 N Moderate i/i N N N
307-5-3 N +A
Moderate i/i
NN N
307-5-4 N Moderate i/i N N N
307-5-5 N Intense i/i N N N
I/I: Inflammation and infiltration.
+10A: Numerous nests of T. cruzi amastigotes.
+A: 1-3 nests of T. cruzi amastigotes.
N: Negative.
doi:10.1371/journal.pntd.0000825.t005
Table 6. Inhibition of other proteases by K11777 and WRR-
483.
IC50 (nM)
Protease K11777 WRR-483
Cathepsin B 5.7 3.960.1
Cathepsin C 0.4 7.060.9
Cathepsin K 25 No inhibition
Cathepsin L 0.2 5364
Cathepsin S 0.6 1.460.01
Cathepsin V 1.2 33564
Papain 0.4 373644
doi:10.1371/journal.pntd.0000825.t006
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solvent, in structures that contain a hydrophobic P2 moiety which
is not conducive to forming a salt bridge, hydrogen bond or
another constructive electrostatic contact.[10,12]
The overall structure of 2AIM and the currently described
structure are globally similar. Superimposition of the two
structures results in an RMS distance of 0.469 A ˚. However, the
two structures have distinct interactions between the P2 arginine
and the S2 glutamate. While the arginine side chains are similarly
oriented at the Cb and Cc positions, Cd is positioned differently,
as a result of a rotation of ca. 180u about the Cb-Cc bond. This
results in a subsequently different positioning of the remaining
atoms in the moiety. The arginine Ne of WRR-483 sits
approximately where NH1 of the Z-Arg-Ala-FMK was positioned,
and one terminal nitrogen of WRR-483 is approximately in the
same position as the corresponding nitrogen of the FMK inhibitor.
The other terminal nitrogen of WRR-483 is directed towards
solvent (Figure 4). The conformation of the S2 glutamate is also
different between the two structures. While still largely directed
into the S2 pocket, Glu208 in cruzain-WRR-483 is less fully
anchored to the arginine and therefore is not as well contained.
There are several interpretations for the rather unexpected anti-
parasitic properties of WRR-483. It is conceivable that WRR-483
is inhibiting more than one parasitic protease. Other potential
targets include the cathepsin B-like protease[40] and cruzipain-2,
an isoform of cruzain which was reported to be active against
substrates containing an arginine group in the P2 position.[41]
Protease profiling studies indicate that WRR-483 is only active
against a few members of the cathepsin family. Also, we have
previously demonstrated that WRR-483 is a potent inhibitor of the
cathepsin L-like cysteine protease, EhCP1, of E. histolytica, and is
much more effective against EhCP1 than K11777. [39] Thus, it is
Figure 3. Structure of WRR-483 bound to cruzain. (A) Crystallographic unit of the WRR-483-cruzain complex. (B) View of the active site of
cruzain. The catalytic Cys25 and residues involved in binding to the inhibitor are also shown. Figures prepared with PyMol.
doi:10.1371/journal.pntd.0000825.g003
Figure 4. Comparison of the binding modes of WRR-483 and Z-
RA-FMK. Superimposition of the cruzain-WRR-483 structure (blue) on
cruzain-Z-RA-FMK (yellow). Bound inhibitors are colored as their
respective cruzain model. The glutamate residue in the S2 pocket
which binds to the guanidine moiety of the inhibitor (Glu205 and 208
for Z-RA-FMK and WRR-483, respectively) are highlighted. Figure
prepared with PyMol.
doi:10.1371/journal.pntd.0000825.g004
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cathepsin L-like cysteine protease in T. cruzi as well.
Another possibility is that the WRR-483 inhibits cruzain either
located on the cell membrane or released by the parasite, and not
in the lysosome. The inhibitor is hydrophilic in nature, primarily
due to the guanidine group, and is more active at physiological
pH, making it very favorable in the extracellular environment.
Parasite cysteine proteases function in a broader pH profile than
their host orthologues, which makes them more susceptible to the
inhibitor. As a part of the host cell invasion mechanism, cruzain is
secreted by T. cruzi trypomastigote to release an invasion factor
from the parasite membrane.[42] Selective inhibition of the
released extracellular cruzain, in effect, could lead to inhibition of
host invasion. This was also observed in the study of invasion by E.
histolytica. In this case, WRR-483 was found to be effective in
reducing host invasion by inhibiting the cysteine proteasethat is
released by the organism.[39]
In this study, we have identified WRR-483, as an effective agent
to treat acute Chagas’ disease in a murine model. This compound
was as effective as the lead compound, K11777, in eliminating
parasite proliferation despite displaying modest potency against
cruzain. The crystal structure of WRR-483 complexed to cruzain
was solved and established the binding mode of the inhibitor to the
enzyme. This structure was highlighted by the formation of a salt
bridge between the guanidine moiety of the inhibitor and Glu208,
but in a different conformation when compared to another
structure of cruzain bound to a different arginine-containing
inhibitor. WRR-483 has recently completed pharmacokinetic and
toxicology studies (SRI international) and was shown to possess a
decent pharmacokinetic profile (Cl=27.5 mL/min/kg, Vd=
15.1 L/kg, t1/2=6.4 h at 10 mg dose iv) but low oral bioavail-
ability due to the polar arginine residue (%F,1%). The no
observed adverse effect level (NOAEL) is higher than 100 mg/kg.
These data suggest that WRR-483 may be useful for treating
parasitic infections like T. cruzi as an IV agent, or E. histolytica
infections of the intestinal tract. Further studies to understand the
precise mechanism of trypanocidal action of WRR-483 and design
of analogs with improved bioavailability are currently underway.
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